Hemab Therapeutics Holdings (COAG) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 34 110 sessions, May 1, 2026 to October 7, 2026
- Largest daily move
- -25.5% close of May 4, 2026
- 1-month change
- -35.5% closing prices, September 4, 2026 to October 7, 2026
Company Description
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. The company focuses on treatments intended to address rare bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its common stock trades on the Nasdaq Global Select Market under the symbol COAG.
The company's lead program is sutacimig (HMB-001), a bispecific antibody being developed as a prophylactic therapy for Glanzmann thrombasthenia and Factor VII deficiency. Hemab's work is centered on coagulation biology and the development of therapeutic candidates for patients with inherited or rare bleeding disorders.
Hemab reports one operating segment focused on the research and development of prophylactic therapeutics for bleeding disorders. As a clinical-stage biotechnology issuer, its operating model is based on advancing drug candidates through research, development, and regulatory processes before any potential commercialization.
Stock Performance
Hemab Therapeutics Holdings (COAG) closed at $28.64 on October 7, 2026. Over the past month, the price has lost 35.5%.
COAG Metrics & Rankings
Price returns through October 7, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Hemab Therapeutics Holdings has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include management, clinical trial, earnings. View all COAG news →
SEC Filings
Hemab Therapeutics Holdings has filed 10 recent SEC filings, including 5 Form SCHEDULE 13G, 2 Form 8-K, 1 Form 3, 1 Form 4. The most recent filing was submitted on September 25, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all COAG SEC filings →
Financial Highlights
Upcoming Events
Prix Galien Awards Ceremony
Phase 1 data release
Hemab Therapeutics Holdings has 2 upcoming scheduled events. The next event, "Prix Galien Awards Ceremony", is scheduled for October 29, 2026 (in 21 days). Investors can track these dates to stay informed about potential catalysts that may affect the COAG stock price.
Short Interest History
Short interest in Hemab Therapeutics Holdings (COAG) currently stands at 2.6 million shares, up 25.3% from the previous reporting period, representing 6.3% of the float. Since May 2026, short interest has increased by 248.1%.
Days to Cover History
Days to cover for Hemab Therapeutics Holdings (COAG) currently stands at 7.5 days, up 25% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since May 2026, the figure has increased by 518%. Across the settlements charted above, it has ranged from 1.2 to 7.5 days.
COAG Company Profile & Sector Positioning
Hemab Therapeutics Holdings (COAG) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.